Vaccine specialist Dynavax (NASDAQ: DVAX) climbed more than 14% higher on Monday. It’s little wonder: The company announced the coronavirus jab it co-developed with Taiwan’s Medigen has been rolled out in the populous Asian nation.
Every Dynavax watcher knew this day was coming; still, it’s encouraging that MVC-COV1901 has been efficiently produced and launched. After all, the vaccine received its Emergency Use Authorization (EUA) from Taiwan’s health ministry barely over one month ago.
Image source: Getty Images.